Application of evolutionary principles to cancer therapy

Cancer Research

Volumn 75, Issue 22, 2015, Pages 4675-4680

  Enriquez Navas, Pedro M ^a   Wojtkowiak, Jonathan W ^a   Gatenby, Robert A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ERSATZDROGE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VERAPAMIL;

ADAPTIVE IMMUNITY; BREAST CANCER CELL LINE; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CELL DEATH; CELL INVASION; CELL PROLIFERATION; EVOLUTION; GENOTYPE; HEART ARRHYTHMIA; HUMAN; MAXIMUM TOLERATED DOSE; METRONOMIC DRUG ADMINISTRATION; NEOPLASM; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; TUMOR CELL; TUMOR EVOLUTION; TUMOR VOLUME; UPREGULATION; ANIMAL; MOLECULAR EVOLUTION; NEOPLASMS; PATHOLOGY;

ANIMALS; EVOLUTION, MOLECULAR; HUMANS; NEOPLASMS;

EID: 84955465654     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1337     Document Type: Review

References (36)

1. Gatenby RA. A change of strategy in the war on cancer. Nature 2009; 459:508-9.
2. Axtell RC, Arends JJ. Ecology and management of arthropod pests of poultry. Annu Rev Entomol 1990;35:101-26.
3. Renton M, Busi R, Neve P, Thornby D, Vila-Aiub M. Herbicide resistance modelling: past, present and future. Pest Manag Sci 2014;70:1394-404.
4. Aktipis CA, Kwan VS, Johnson KA, Neuberg SL, Maley CC. Overlooking evolution: A systematic analysis of cancer relapse and therapeutic resistance research. PLoS ONE 2011;6:e26100.
5. Anderson AR, Quaranta V. Integrative mathematical oncology. Nature Rev Cancer 2008;8:227-34.
6. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014;54: 716-27.
7. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABCtransporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010;10:147-56.
8. Wind NS, Holen I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int J Breast Cancer 2011;2011:967419.
9. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989;60:815-8.
10. Thews O, Nowak M, Sauvant C, Gekle M. Hypoxia-induced extracellular acidosis increases p-glycoprotein activity and chemoresistance in tumors in vivo via p38 signaling pathway. Adv Exp Med Biol 2011;701: 115-22.
11. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat Rev Cancer 2009;9:665-74.
12. Moulder S. Intrinsic resistance to chemotherapy in breast cancer. Women's Health 2010;6:821-30.
13. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-9.
14. Rodrigues DS, de Arruda Mancera PF. Mathematical analysis and simulations involving chemotherapy and surgery on large human tumours under a suitable cell-kill functional response. Math Biosci Eng 2013;10:221-34.
15. Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, Ria R, et al. Metronomic chemotherapy from rationale to clinical studies: A dream or reality? Crit Rev Oncol Hematol 2015;95:46-61.
16. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res 2009;69:4894-903.
17. Kam Y, Das T, Tian H, Foroutan P, Ruiz E, Martinez G, et al. Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges." Int J Cancer 2015;136:E188-96.
18. Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res 2012;72:6362-70.
19. Jansen G, Gatenby R, Aktipis CA. Opinion: Control vs. eradication: Applying infectious disease treatment strategies to cancer. Proc Natl Acad Sci U S A 2015;112:937-8.
20. Neve P, Vila-Aiub M, Roux F. Evolutionary-thinking in agricultural weed management. New Phytol 2009;184:783-93.
21. Oliveira EE, Guedes RNC, TotolaMR, De Marco P Jr. Competition between insecticide-susceptible and -resistant populations of the maize weevil, Sitophilus zeamais. Chemosphere 2007;69:17-24.
22. Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira RJ, Carvalho F, de Lourdes Bastos M, et al. Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther 2015;149:1-123.
23. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011; 3:90ra59.
24. Ayala FJ, Dobzhansky T. "Nothing in biology makes sense except in the light of evolution": Theodosius Dobzhansky: 1900-1975. J Hered 1977; 68:3-10.
25. Gatenby RA, Frieden BR. Inducing catastrophe in malignant growth. Math Med Biol 2008;25:267-83.
26. Broxterman HJ, Pinedo HM, Kuiper CM, Kaptein LC, Schuurhuis GJ, Lankelma J. Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells. FASEB J 1988;2:2278-82.
27. Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 2010;596:341-58.
28. Gatenby RA, Brown J, Vincent T. Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res 2009;69: 7499-502.
29. Maley CC, Reid BJ, Forrest S. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol Biomarkers Prev 2004;13:1375-84.
30. Fuentes-Hernandez A, Plucain J, Gori F, Pena-Miller R, Reding C, Jansen G, et al. Using a sequential regimen to eliminate bacteria at sublethal antibiotic dosages. PLoS Biol 2015;13:e1002104.
31. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12:878-87.
32. Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: A dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther 2010; 10:983-91.
33. Wang W-X, Ni X, Lai Y-C, Grebogi C. Optimizing controllability of complex networks by minimum structural perturbations. Phys Rev E Stat Nonlin Soft Matter Phys 2012;85:026115.
34. Ibrahim-Hashim A, Cornnell HH, Abrahams D, LloydM, Bui M, Gillies RJ, et al. Systemic buffers inhibit carcinogenesis in TRAMP mice. J Urol 2012;188:624-31.
35. Gatenby RA, Grove O, Gillies RJ. Quantitative imaging in cancer evolution and ecology. Radiology 2013;269:8-15.
36. Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, et al. Effect of bipolar androgen therapy for asymptomatic men with castrationresistant prostate cancer: results from a pilot clinical study. Sci Transl Med 2015;7:269ra2.